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The BDNF Val66Met polymorphism regulates
glucocorticoid-induced corticohippocampal remodeling
and behavioral despair
M Notaras1,2,3, X Du2,4, J Gogos5, M van den Buuse1,6,7,8 and RA Hill1,2,4
The BDNF Val66Met polymorphism has been associated with sensitivity to stress and affective disorders. We therefore sought
to model the inter-causality of these relationships under controlled laboratory conditions. We subjected humanized BDNF
Val66Met (hBDNFVal66Met) transgenic mice to a history of stress, modeled by chronic late-adolescent corticosterone (CORT)
exposure, before evaluating affective-related behavior using the forced-swim test (FST) in adulthood. While hBDNFMet/Met mice
had a depression-like phenotype in the FST irrespective of CORT, hBDNFVal/Val wildtype mice had a resilient phenotype but
developed an equally robust depressive-like phenotype following CORT. A range of stress-sensitive molecules were studied across
the corticohippocampal axis, and where genotype differences occurred following CORT they tended to inversely coincide with the
behavior of the hBDNFVal/Val group. Notably, tyrosine hydroxylase was markedly down-regulated in the mPFC of hBDNFVal/Val mice
as a result of CORT treatment, which mimicked expression levels of hBDNFMet/Met mice and the FST behavior of both groups. The
expression of calretinin, PSD-95, and truncated TrkB were also concomitantly reduced in the mPFC of hBDNFVal/Val mice by CORT.
This work establishes BDNFVal66Met genotype as a regulator of behavioral despair, and identifies new biological targets of BDNF
genetic variation relevant to stress-inducible disorders such as depression.
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INTRODUCTION
Affective disorders, such as major depressive disorder, have an
estimated lifetime prevalence of ~ 20.8%,1 and are projected to
become a leading cause of long-term disability.2 The neurobiology
of affective disorders has advanced rapidly, and has led to the
identification of a number of core pathology that includes
reduced neurotrophic support and synaptic remodeling3 within
brain regions such as the hippocampus4,5 and medial prefrontal
cortex (mPFC).5
One environmental factor that has consistently been associated
with the onset and maintenance of affective disorders is stress.
Clinical markers of stress exposure, such as daily life stress, history
of stressful life events, and trauma have all been shown to play a
role in aspects of affective disorder symptomology or risk, and
collectively support the assertion that both developmental and
ongoing stress are capable of inducing depressive disorders.6 In
rodent models, exposure to a broad range of stress paradigms has
led to the identification of several remodeling events that
putatively occur as a result of glucocorticoid stress hormones
within the brain. These include widespread alterations within the
hippocampus, including reductions in dendritic spine branching
and complexity,7 changes in the expression of brain-derived
neurotrophic factor (BDNF),8 NMDA receptor subunit
reorganization9 and synaptic scaffolding proteins such as the
excitatory postsynaptic molecule PSD-9510 and presynaptic
marker synaptophysin.11 A similar pattern of reorganization
following stress also occurs in other brain regions including the
mPFC, which appears particularly vulnerable to stress-induced
alterations in noradrenergic activity12,13 and the maturation of
inhibitory interneuron networks.14
BDNF has been widely studied as a susceptibility factor for both
stress and affective dysregulation. BDNF plays a fundamental role
in brain development, neuronal differentiation and synaptic
plasticity.15 It has been suggested that BDNF is a transducer of
antidepressant effects,16 principally because BDNF is recruited by
antidepressant therapeutics (as well as other mood disorder
treatments such as electroconvulsive shock17 and transcranial
magnetic stimulation therapies18) and is suppressed by many risk
factors for mood disorders including stress.19 In rodent models,
BDNF also mediates behavioral endophenotypes of relevance to
affective disorders,20,21 while in clinical samples serum BDNF
concentrations predict the effectiveness of selective-serotonin
reuptake inhibitors in the treatment of depression.22
The BDNF Val66Met polymorphism, named after a Valine→
Methionine substitution at codon 66 within the BDNF prodomain,
has been widely studied as a risk factor for affective disorders due
to its common frequency and established functionality.15 Speci-
fically, the Val66Met substitution results in the diminished activity-
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dependent release of BDNF,23 deficient hippocampus-dependent
memory function24 and a lack of response to antidepressant
therapeutics in BDNFVal66Met knock-in mice.24,25 However, the role
of this gene variant as a risk factor for mood disorders and
modulator of antidepressant response has been the source of
much controversy given non-concordant results between associa-
tion studies (see ref. 15 for extensive review). These inconsistent
clinical findings strengthen the case for animal models in
providing well controlled findings on the biological mechanisms
which underpin stress responsivity, as well as antidepressant
response. That said, a number of reports have emerged in recent
years which suggest that the Val66Met variant may induce HPA
axis dysfunction,25 which we previously hypothesized may lead to
a long-lasting sensitivity to glucocorticoid stress hormones15 and
thus vulnerability to affective dysregulation. In support of this
hypothesis, it has been previously published that childhood
adversity may unmask an effect of the 66Met allele on
depression,26 while in otherwise healthy adults a history of sexual
trauma has been shown to moderate the expression of depressive
symptoms among 66Met allele carriers.27 Of concern, however, is
a report which suggests that first-episode depression patients that
carry BDNFVal/Met and BDNFMet/Met genotypes are more likely to
have experienced stressful life events than BDNFVal/Val genotype
controls,28 suggesting that this variant may induce a stress-
sensitivity loop whereby 66Met allele carriers are not just more
sensitive to the effects of stress but are also more likely to
experience stressful life events.
Therefore, we sought to resolve what effect BDNFVal66Met
genotype has on corticohippocampal molecular remodeling and
depression-related behavioral despair using the forced-swim test
(FST), and whether a phenotype was dependent on, or unmasked
by, a history of chronic stress.
MATERIALS AND METHODS
Genetic construct of humanized BDNFVal66Met mice
The BDNF gene is highly conserved between species,29 and despite
differences in promoter structure the coding exon of mouse Bdnf closely
resembles that of human BDNF. To generate the Val66Met knock-in
human-BDNF expressing (hitherto referred to as hBDNFVal66Met) mice, a
274bp region was amplified from one BDNFVal/Val and one BDNFMet/Met
human donor and inserted into the mouse BDNF gene, replacing the
respective murine sequence.30 Extensive procedural details (including
details of recombination probes and targeting constructs) are available in a
previous publication.30 Once generated, BDNFHuman Val/+ mice were
crossed with BDNFHuman Met/+ mice to generate hBDNFVal/Met mice, which
were subsequently used as breeders to produce hBDNFVal/Val and
hBDNFMet/Met mice. All mice were maintained on a C57BL/6 background.
Mice were bred and group-housed in individually ventilated cages under
standard lighting conditions (12 h light cycle) and provided ad libitum
access to food and water. All experimental procedures were approved by
the Florey Institute of Neuroscience’s animal ethics committee, and
conducted in accordance with guidelines set by the National Health and
Medical Research Council of Australia.
Late-adolescent chronic CORT protocol
Chronic adolescent stress was simulated by treating pseudorandomly
selected mice with 25 mg l− 1 of the mouse stress hormone, corticosterone
(CORT), which was dissolved in the animal’s drinking water, as previously
described.31 This dosage was selected based on previous work which has
shown that this low-dosage recapitulates depression-like brain and
behavioral phenotypes without peripheral side-effects that may influence
animal health.32 Importantly, chronic CORT delivered via drinking water
also recapitulates several translationally relevant aspects of daily life stress,
as it follows a diurnal cycle and is capable of inducing persistent alterations
in anxiety- and affective-related behavior that can be rescued by anti-
depressant treatment.32 This model thus allows the long-term evaluation
of stress-induced changes in brain chemistry or behavioral outputs that
last beyond the disruption of the HPA axis during treatment,32,33 as is
similar to the lasting effects of early life stress on the chronicity of
depression-related symptoms in humans.34 Animals assigned to the
chronic CORT group received the treatment solution between weeks six
to nine, a developmental period which is similar to late adolescence in
humans as evidenced by a late spike in the production of sex-steroid
hormones.35 Mice allocated to the control group received unaltered water
over this timeframe. There was a two-week washout period following
treatment, so that the HPA axis and circulating glucocorticoids levels could
recover,33 before behavioral testing commenced.
Forced-swim test
The forced-swim test was used as our representative model of learned
helplessness and behavioral despair. Mice were ~ 15 weeks of age at
testing. Four swim chambers (maximum volume of 2 l) were filled with 1.7 l
of water pre-heated to 21 °C, and were separated by white dividers. Before
experimentation, mice were habituated for one hour in the test room.
Following habituation, mice were individually placed into a swim chamber
and allowed to swim for six minutes. Behavior was recorded for offline
analysis, with time spent immobile – defined as a lack of swimming
movement of a duration equal to or exceeding one second – being
quantified by two observers who were unaware of group allocations. The
primary outputs were latency to immobility, the time-course of immobility
over the test session and the average immobility over the last 4 minutes of
testing.
Preparation of brain lysates and western blot
Experimental mice were killed via cervical dislocation one week after
completing behavior. Brains were snap-frozen on dry ice, stored at − 80 °C
and later dissected with a brain matrix according to the Paxinos and
Watson atlas.36 The dorsal hippocampus (DHP), ventral hippocampus (VHP)
and mPFC (which included the prelimbic, infralimbic and cingulate
cortices) were chosen as our primary regions of interest given their
involvement in mood disorders. Once dissected, protein was extracted and
aliquoted into 50 μg protein samples before undergoing SDS–PAGE and
transfer to nitrocellulose membrane, as previously described.31 Membranes
were incubated in 5% bovine serum albumin in Tris-buffered saline with
primary antibody overnight (β-Actin: 1:10000, Sigma-Aldrich, Sydney, NSW,
Australia; Calretinin: 1:1000, Swant, Switzerland cr7697; fl. and tr.TrkB:
1:1000, Santa Cruz Biotechnology, Dallas, TX, USA H181; pTrkBY515: 1:1000,
Abcam, Cambridge, UK ab109684; Gephyrin: 1:1000, Abcam ab32206;
NR2A: 1:1000, Abcam ab14596; NR2B/NR1: 1:200, Abcam ab110; PSD-95:
1:1,000, Abcam ab18258; Synaptophysin: 1:400, Sigma-Aldrich s5768;
Tyrosine Hydroxylase: 1:1,000, Millipore, Bayswater, VIC, Australia ab152).
Blots were imaged using a LAS-4000 Luminescence Analyzer (Fuji Film Life
Science, Stamford, CT, USA) and analyzed using the TotalLab Quant
Analysis Software (Total Lab, Newcastle, UK). Western blots were repeated
between two to four times to confirm results.
BDNF Enzyme-Linked immunosorbent assay
BDNF expression was quantified using the BDNF Emax ImmunoAssay
System (Promega, Madison, WI, USA), so that an exact concentration
per region could be derived between hBDNFVal66Met genotype groups.
According to the manufacturer, the kit has a sensitivity as low as
15.6 pg μl− 1, with o3% cross-reactivity to other neurotrophins. Assays
were performed according to manufacturer’s instructions. Briefly, a 96-well
plate was coated with 100 μl of anti-BDNF antibody diluted in carbonate-
coating buffer (10 μl:9.99 ml) and incubated overnight. The following
morning, plates were blocked for 1 h with supplied buffer before 100 μl of
BDNF standards and experimental samples were plated in duplicate. After
incubating with shaking for 2 h, 100 μl of an anti-BDNF polyclonal antibody
solution (1:500 diluted in blocking buffer) was added per well and
incubated for a further 2 h. Following washing, 100 μl of diluted anti-IgY
HRP conjugate (1:200 in blocking buffer) was added to wells and incubated
for 1 h. Absorption was correspondingly developed by adding 100 μl of
supplied TMB solution per well and and incubating for 10 min, and
terminated with 100 μl per well of 1 N hydrochloric acid. Absorption was
read at 450 nm using a plate reader.
Statistical analysis
The total sample size of the current study was 166 hBDNFVal66Met mice,
comprising 26 control and 25 CORT-treated hBDNFVal/Val mice, 40 control
and 28 CORT-treated hBDNFVal/Met mice, and 23 control and 24 CORT-
treated hBDNFMet/Met mice. Sampling was based on our prior investigations
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using this mouse line, which have been adequately powered to detect
medium-to-large as well as more subtle effects upon pooling (see below;
refs. 31, 37). Data analysis was undertaken using the IBM SPSS and
Graphpad Prism packages. For tests that only involve between-group
comparisons a 3 (genotype) × 2 (sex) × 2 (treatment) Analysis of Variance
(ANOVA) was conducted, with assumptions being screened for. Within-
group comparisons were analyzed using a Mixed Model ANOVA. SEMs
were used as our measure of variance for all graphing. As no significant
interaction involving the main effect of sex was observed on any given
behavioral or molecular measure, denoting no effect of sex on the main
effects of genotype and treatment, data from male and female mice were
analyzed together to increase power as consistent with previous
investigations.31,37 No exclusion criteria were applied, except for outliers
(defined as values falling outside of ± 2 s.d.). Statistical significance was
set at P=0.05, as per Fisher’s tables, while all between-group comparisons
were corrected for multiple comparisons using Tukey’s or Holm-Sidak’s
method depending on observed power.
RESULTS
hBDNFVal66Met genotype determines vulnerability to stress-related
despair
The FST was used as our model of behavioral despair. Analysis
revealed main effects of hBDNFVal66Met Genotype (F(2,160) = 9.7,
P= 0.0001) and chronic CORT (F(1,160) = 17.5, Po0.0001), as well
as their interaction (F(2,160) = 5.0, P= 0.0077), on immobility. Post-
hoc comparisons of the significant main effects revealed that mice
carrying the hBDNFMet/Met genotype were immobile for signifi-
cantly longer than hBDNFVal/Val mice at baseline (Po0.0001),
while mice treated with CORT were also immobile for significantly
longer than those allocated to the control group (Po0.0001).
Post-hoc analysis of the genotype × treatment interaction revealed
that the chronic CORT treatment selectively increased the
immobility of hBDNFVal/Val mice relative to controls (Po0.0001).
No effect of CORT was detected among the other genotype
groups. No significant differences were observed between groups
for latency to immobility.
Late-adolescent CORT exposure suppresses tyrosine hydroxylase
and calretinin expression in the mPFC of Adult hBDNFVal/Val Mice
Expression of tyrosine hydroxylase (TH), the rate-limiting enzyme
involved in the biosynthesis of catecholamine neurotransmitters
such as noradrenaline,38 has been implicated in suicidality,39 is
altered in depression40,41 and is responsive to antidepressant
therapeutics.42 In addition, gene variants within the TH gene have
also been associated with mood disorder symptomology,43 while
chronic stress may regulate the release of noradrenaline within
the hippocampus44 and prefrontal cortex.12,45 To this end, we
examined whether expression of TH was altered in our three
regions of interest in our hBDNFVal66Met mouse line and whether a
history of chronic CORT treatment alters the expression of this
enzyme in adulthood. There was no effect of hBDNFVal66Met
genotype or history of adolescent CORT exposure on the
expression of TH in the DHP or VHP. However, within the mPFC
a significant hBDNFVal66Met genotype × history of CORT treatment
(F(1, 49) = 4.42, P= 0.041) interaction was observed, whereby
chronic CORT reduced the expression of TH in hBDNFVal/Val mice
by 450% (Po0.001) to levels that were consistent with vehicle
and CORT-treated hBDNFMet/Met mice, which did not differ from
one another. A further main effect of CORT was also detected in
the mPFC (F(1, 49) = 10.6, P= 0.002), however no other main
effects reached significance.
While TH expression in the mPFC largely represents terminal TH
present in projections from the midbrain, there also remains a
subset of cortical TH-immunoreactive cells that are predominantly
bipolar type inhibitory interneurons that selectively express the
calcium-channel binding protein calretinin.46 As such, we next
examined whether the expression of calretinin was altered across
our regions of interest. There were no significant group
differences in the DHP or VHP. However, in the mPFC a
hBDNFVal66Met genotype ×CORT treatment (F(1, 49) = 4.54,
P= 0.038) interaction was once more observed where, like TH,
the expression of calretinin was selectively decreased among the
hBDNFVal/Val group as a function of CORT treatment (Po0.05). No
further main effects or interactions reached significance.
No Effect of hBDNFVal66Met Genotype on Basal BDNF Levels in
Corticohippocampal Regions
BDNF levels were quantified via ELISA so to determine an absolute
concentration of basal BDNF between groups. BDNF expression in
the DHP was not significantly different between hBDNFVal/Val and
hBDNFMet/Met mice, however a significant effect of prior CORT
treatment was detected in this brain region (F(1,30) = 13.73,
P= 0.0009) reflecting that this treatment increased BDNF expres-
sion irrespective of genotype. BDNF expression in the VHP and
mPFC did not significantly differ between the various treatment
and genotype groups. No other main effects or comparisons
reached significance.
Region-Specific Effects of hBDNFVal66Met Genotype and CORT on
TrkB Receptors
We also screened for an effect of hBDNFVal66Met genotype and
history of CORT treatment on the expression of BDNF’s cognate
receptor TrkB. This included assessments of the functional full-
length TrkB (fl.TrkB) receptor, the catalytic domain-lacking and
dominant-negative truncated TrkB (tr.TrkB) receptor,47,48 and the
phosphorylation of TrkBY515. In the DHP, a significant effect of
hBDNFVal66Met genotype was detected for fl.TrkB (F(1, 52) = 8.13,
P= 0.0062). Post-hoc testing revealed that hBDNFMet/Met mice had
higher fl.TrkB expression than hBDNFVal/Val mice in this brain
region (Po0.01). While this genotype effect appeared to be
moderated by an inhibitory effect of CORT on the expression of
TrkB protein in the DHP of hBDNFVal/Val mice, there was no
statistical support for a genotype ×CORT interaction (P= 0.10) in
spite of our relatively large group sizes (in this region, per group,
n= 14). Contrary to this, fl.TrkB was not altered in the VHP or
mPFC. The analysis of tr.TrkB receptor expression revealed a
significant main effect of chronic CORT treatment (F(1, 51) = 9.48,
P= 0.0033) in the DHP, which decreased tr.TrkB expression
irrespective of genotype in this region. In the VHP, a significant
main effect of hBDNFVal66Met genotype (F(1, 52) = 4.7, P= 0.035)
emerged, whereby hBDNFMet/Met mice had lower expression of the
tr.TrkB isoform than hBDNFVal/Val mice (Po0.05). In the mPFC, a
significant main effect of chronic CORT treatment (F(1, 48) = 6.03,
P= 0.018), as well as a hBDNFVal66Met genotype× chronic CORT
treatment interaction (F(1, 48) = 5.57, P= 0.022) emerged for tr.
TrkB availability. Post-hoc analysis revealed that while chronic
CORT treatment tended to decrease the expression of tr.TrkB
irrespective of genotype, the magnitude change in tr.TrkB
expression following CORT treatment was more pronounced
among hBDNFVal/Val mice (Po0.01). Lastly, the only main effect to
reach significance for pTrkBY515 was a history of CORT treatment,
which emerged in the DHP (F(1, 51) = 5.74, P= 0.0203), VHP (F(1,
52) = 22.51, Po0.0001) and mPFC (F(1, 40) = 8.67, P= 0.0054).
Chronic CORT increased basal pTrkBY515, which was normalized to
fl.TrkB levels, in these regions.
hBDNFVal/Val Mice are more vulnerable than hBDNFMet/Met mice to
synaptic protein reorganization following chronic CORT exposure
To assess the effect of hBDNFVal66Met genotype and chronic CORT
exposure on synaptic integrity, expression levels of the excitatory
and inhibitory terminal scaffolding proteins PSD-95 and gephyrin,
as well as the presynaptic vesicle transport molecule, synapto-
physin, were screened in the DHP, VHP and mPFC. In the DHP, a
BDNF val66met glucocorticoid interaction
M Notaras et al
3
Translational Psychiatry (2017), 1 – 11
significant hBDNFVal66Met genotype x CORT interaction was
observed for the expression of synaptophysin (F(1, 43) = 4.34,
P= 0.043), whereby chronic CORT reduced its expression in the
DHP of hBDNFVal/Val mice but not hBDNFMet/Met mice (Po0.01). In
addition to this, the expression of PSD-95 was found to
significantly depend on hBDNFVal66Met genotype in the DHP (F(1,
50) = 18.66, Po0.0001); reflecting that hBDNFMet/Met mice had
higher expression levels of PSD-95 than hBDNFVal/Val mice in this
region. A history of chronic CORT exposure in adolescence also
significantly decreased the expression of PSD-95 (F(1, 50) = 13.76,
P= 0.0005), but did not interact with genotype. Similarly, no effect
of hBDNFVal66Met genotype was detected on the expression of
gephyrin in the DHP, which was reduced irrespective of genotype
by history of CORT exposure (F(1, 52) = 9.21, P= 0.0037). In the
VHP, none of the main effects reached significance nor did they
interact to determine the expression of synaptophysin, PSD-95 or
gephyrin, suggesting that the DHP but not VHP is selectively
sensitive to the effect of hBDNFVal66Met genotype and the long-
term effect of chronic adolescent CORT treatment. In the mPFC,
none of the main effects reached significance for the expression of
our synaptic proteins of interest. However, a subtle but significant
hBDNFVal66Met genotype × chronic CORT treatment interaction
emerged for the expression of PSD-95 (F(1, 48) = 6.12, P= 0.017).
Post-hoc testing revealed that, once more, it was the hBDNFVal/Val
wildtype genotype which was associated with reduced PSD-95
expression following the chronic CORT treatment (Po0.05). All
other comparisons failed to reach significance.
hBDNFVal66Met genotype does not alter NMDA receptor subunit
expression
Given the role of PSD-95 as a scaffolding protein involved in
securing NMDA receptors to the cell membrane,49 that
BDNFVal66Met genotype is associated with altered NMDA receptor
physiology50–52 and that NMDA receptor subunits may modulate
FST performance,53–55 we next screened for differences in
expression of the NMDA receptor NR2A, NR2B and NR1 subunits.
In the DHP, there was a main effect of chronic CORT treatment on
NR2A (F(1, 52) = 4.73, P= 0.034), NR2B (F(1, 52) = 4.06, P= 0.049)
and NR1 (F(1, 46) = 7.97, P= 0.007) subunit expression, where a
history of CORT decreased the expression of these subunits
irrespective of genotype. In the VHP a main effect of CORT was
observed for NR2A (F(1, 52) = 11.55, P= 0.001) and NR2B (F(1,
51) = 19.27, Po0.0001) expression, albeit in the opposite direction
to the effect seen in the DHP. No effect of hBDNFVal66Met genotype
or history of CORT treatment emerged for NR1 within the VHP.
Lastly, in the mPFC, the only effect to reach significance was that
of CORT on the expression of the NR2B subunit (F(1, 52) = 17.25,
P= 0.0001), where expression was increased as a result of CORT
treatment irrespective of hBDNFVal66Met genotype. No other main
effects or interactions reached significance.
DISCUSSION
The aim of the current study was to examine the effect of the
BDNF Val66Met polymorphism on behavioral despair at baseline,
Figure 1. hBDNFVal66Met genotype and history of CORT treatment regulate immobility in the Forced-Swim Test (FST). (a) A main effect of
genotype was detected at baseline for immobility, where hBDNFMet/Met mice were immobile for significantly longer than hBDNFVal/Val mice. An
interaction between genotype and CORT treatment was also observed, where the hBDNFVal/Val mice were most susceptible to the effects of
CORT on immobility. (b) No main effect or interaction was detected for average latency to immobility. (c–e) An analysis of immobility as a time-
course confirmed the selective effect of CORT on this genotype group. All data are presented as mean± s.e.m.; ***Po0.001, ****Po0.0001.
Per group, n= 23–40.
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and whether a depression-like phenotype was unmasked or
modulated by a history of chronic stress. The FST was used as our
representative paradigm for behavioral despair, while a CORT
exposure paradigm was chosen as our model of stress due to its
specificity in receptor action in the brain and diurnal cycle which
recapitulates the core features of chronic life stress. Our data
supported our hypothesis that the hBDNFVal66Met genotype gates
learned helplessness in adulthood, and that a history of CORT
exposure during late adolescence acts to regulate this effect.
Specifically, we report that while hBDNFMet/Met mice have a robust
learned helplessness phenotype at baseline, following chronic
CORT the hBDNFVal/Val genotype group develops a behavioral
despair phenotype that is just as robust as that of the hBDNFMet/Met
group (Figure 1).
The presence of a 66Met-derived despair phenotype at baseline
in our hBDNFVal66Met model is consistent with the broader
literature on the role of BDNF in animal models of depression,
where deficient BDNF expression results in social defeat and
learned helplessness phenotypes,20,21 and likely occurs via the
disrupted activity-dependent release of BDNF induced by the
66Met substitution. In favor of the construct validity of this model,
our behavioral data are also consistent with clinical data from
population genetic studies which have reported evidence that the
66Met allele may be associated with affective disorders, as well as
clinical components of these disorders.15 However, this clinical
evidence has been inconsistent,15 possibly due to the involvement
of interaction factors such as vulnerability to stress. In this respect,
our observation that this enduring learned helplessness pheno-
type occurs at baseline our hBDNFMet/Met genotype group, but
that the hBDNFVal/Val wildtype genotype produces a convergent
phenotype following a history of simulated stress exposure,
provides support for a role of the BDNFVal66Met variant in mood
disorders, while also providing an explanation for why results may
have failed to replicate between some studies (as a long-term
effect of prior stress or trauma may not have been stratified as
covariates). In addition to this, the current data also extend our
prior report using this mouse line and model of stress31 by
establishing that glucocorticoid stress hormones differentially
interact with BDNFVal66Met genotype to alter behavior depending
on the system being studied and construct being measured.
Specifically, we previously replicated a gene-dosage effect of the
hBDNFMet/Met genotype on fear conditioned memory and short-
term spatial memory which we found could be ‘rescued’ by
chronic CORT,31 while in other behavioral paradigms, such as
prepulse inhibition, chronic CORT exposure unveiled a hetero-
zygote disadvantage phenotype among hBDNFVal/Met mice
relative to both homozygous genotype groups.37 In this respect,
we can confirm that for behavioral despair on the FST an effect of
hBDNFVal66Met genotype emerges at baseline, and that chronic
CORT exposure induces a deficit among hBDNFVal/Val mice, while
having no further effect on hBDNFVal/Met mice or hBDNFMet/Met
mice (see Figure 1). Thus, hBDNFMet/Met mice perform on the FST
similarly to CORT-treated hBDNFVal/Val mice, implicating that the
Val66Met variant induces vulnerability to behavioral despair.
Our investigation of the mechanism that underscores this
convergence in FST phenotype between hBDNFMet/Met and CORT-
treated hBDNFVal/Val mice revealed several differences in the long-
term molecular adaptation to chronic CORT treatment between
hBDNFVal/Val and hBDNFMet/Met mice. Specifically, in the mPFC, a
history of chronic CORT treatment decreased the expression of TH
in hBDNFVal/Val mice to levels consistent with the hBDNFMet/Met
genotype group (see Figure 2c), which inversely corresponded
with the FST performance of both genotype groups. TH within the
cortex is believed to largely originate from terminals of
catecholamine projections that emanate from within the mid-
brain. These projections originate from brain regions responsible
for producing dopamine and noradrenaline, which have both
been implicated in the adaptation to stress56 and mood
Figure 2. hBDNFVal66Met genotype and chronic CORT exposure interact to selectively reduce the expression of Tyrosine Hydroxylase (TH) and
calretinin in the mPFC but not hippocampus. While there was no effect of genotype or chronic CORT treatment on TH (a, b) or calretinin (d, e)
expression in the DHP or VHP, the expression of both TH (c) and calretinin (f) was found to be reduced in hBDNFVal/Val mice following CORT in
the mPFC. All data are presented as mean± s.e.m.; *Po0.05, **Po0.01, ***Po0.001 and ****Po0.0001. Per group, n= 13–14.
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Figure 3. No effect of hBDNFVal66Met genotype on basal BDNF protein levels in the (a) DHP, (b) VHP or (c) mPFC. The only main effect to reach
significance in these regions was a history of chronic CORT treatment in the DHP, which increased BDNF expression levels independent of
hBDNFVal66Met genotype. All data are presented as mean± s.e.m.; ***Po0.001. Per group, n= 8–11.
Figure 4. Effects of hBDNFVal66Met genotype and prior CORT exposure on TrkB isoforms. (a) hBDNFMet/Met mice have (subtly) higher fl.TrkB
expression relative to hBDNFVal/Val mice in the DHP, while chronic CORT tends to (b) decrease tr.TrkB expression while (c) increasing TrkBY515
phosphorylation in this brain region. In the VHP, (d) fl.TrkB was unchanged however (e) hBDNFMet/Met mice tended to have lower tr.TrkB
expression than hBDNFVal/Val mice. (f) CORT treatment increased pTrkBY515 phosphorylation in the VHP. In the mPFC, (g) fl.TrkB was once more
unchanged. (h) However, a significant genotype × treatment interaction emerged for tr.TrkB expression whereby hBDNFVal/Val mice selectively
responded to chronic CORT. Following CORT, expression levels of tr.TrkB in the mPFC of hBDNFVal/Val mice were reminiscent of those observed
in the mPFC of hBDNFMet/Met mice. (i) Lastly, as in the DHP and VHP, a history of CORT also increased pTrkBY515 phosphorylation in the mPFC.
All data presented as mean± SEM; *Po0.05, **Po0.01, and ***Po0.001. Per group, n= 9–14.
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disorders.57 Therefore, our TH phenotype may be related to both
dopamine and/or noradrenaline activity. However, as BDNF+/Met
mice have increased noradrenergic transporter expression within
the locus coeruleus,25 and considering that the noradrenergic
agent desipramine (but not the SSRI fluoxetine) rescues the FST
phenotype of BDNF+/Met mice following restraint stress,25 the
possibility that our TH phenotype is linked to alterations in
noradrenergic activity remains a tantalizing possibility. Noradrena-
line plays an important role in modulating the behavioral
response to stress, and it is of note that various stress treatments
increase noradrenaline release12 and sensitization58,59 within the
mPFC. Importantly, TH is found within noradrenergic terminals in
the PFC,60,61 and selective noradrenaline reuptake inhibitors (but
not selective serotonin reuptake inhibitors) reduce Fos-like
immunoreactivity in the mPFC following testing on the FST.62 As
hyporeactivity of the mPFC in response to stress may provide a
foundation for stress-related behavioral traits,63 it would be of
interest to consider measurements of catecholamine activity
within the mPFC of hBDNFVal66Met mice, both at baseline and
following stress, in future studies. That said, other than neuronal
terminal TH, a subset of TH-immunoreactive cells may also exist in
the PFC64 and these cells are believed to be inhibitory
interneurons based on their morphology and colocalization with
both GAD and calretinin.46 The functionality of these neurons is
unknown.46 Nevertheless, we also quantified calretinin within the
mPFC and found it too was concomitantly reduced selectively in
the hBDNFVal/Val genotype group as a result of CORT treatment
(Figure 2f). As such, it is possible that the significant reduction in
TH within the mPFC of CORT-treated hBDNFVal/Val mice may arise
from an alteration in terminal TH and noradrenergic innervation
Figure 5. hBDNFVal66Met genotype alters synaptic protein expression within the DHP and mPFC but not VHP. (a) Within the DHP, the expression
of synaptophysin was labile to remodeling by chronic CORT as a function of hBDNFVal66Met genotype, where hBDNFVal/Val mice were selectively
vulnerable to the long-term effect of CORT. (b) The expression of PSD-95 in the DHP was found to be dependent on hBDNFVal66Met genotype.
hBDNFMet/Met mice had significantly higher PSD-95 expression, an excitatory post-synaptic marker and scaffolding protein, than hBDNFVal/Val
mice. While an effect of CORT on the expression of PSD-95 in the DHP was also detected, which decreased the expression of this scaffolding
protein, this effect was independent of genotype. (c) This effect of CORT was recapitulated for the expression of inhibitory terminal marker
gephyrin. There were no significant differences in synaptic protein reorganization in the VHP (d-f) In the mPFC, there were no detectable
alterations in the expression of synaptophysin (g) or gephyrin (i), however a subtle hBDNFVal66Met × chronic CORT treatment interaction
emerged for the expression of PSD-95 which resulted in a selective decrease of this marker among the hBDNFVal/Val group as a consequence of
CORT treatment (h). All data are presented as mean± SEM; *Po0.05, **Po0.01, ***Po0.001, and ****Po0.0001. Per group, n= 13–14.
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by ascending projections, a selective loss of TH-immunoreactive
calretinin interneurons within the mPFC, or a combination of both
outcomes.
Importantly, long-lasting changes in basal BDNF expression
following CORT does not appear to underscore these behavioral
and molecular phenotypes. The DHP was the only structure that
exhibited a change in BDNF expression across our groups
(Figure 3a), where an indiscriminate effect of prior CORT exposure
increased total BDNF. While it is unclear why only the DHP
exhibited this shift in expression, it is possible that the DHP is
developmentally more sensitive to the effects of CORT than the
VHP. This explanation is consistent with genotype-specific
alterations in the developmental expression of GRs within the
DHP of hBDNFVal66Met mice, as we have previously reported (see
supplementary data of ref. 31), which establishes that differences
in the developmental trajectory of the hippocampal longitudinal
axis may result in critical periods of vulnerability to stress.
Likewise, neither fl.TrkB expression nor phosphorylation
(Figure 4) appeared to be associated with the behavioral and
molecular phenotypes reported here. However, tr.TrkB receptors
were found to be selectively down-regulated in the mPFC of
hBDNFVal/Val mice following CORT (Figure 4h). As tr.TrkB receptors
have dominant-negative effects upon fl.TrkB signaling,47,48 the
down-regulation of this isoform in the mPFC of CORT-treated
hBDNFVal/Val mice may serve to indirectly increase BDNF binding
to fl.TrkB during activity-dependent processing. This result thus
represents a novel effect of stress hormones upon the BDNF-TrkB
signaling pathway that has not been previously described in this
brain region as a result of BDNF genetic variation and stress
exposure. In addition to a decrease in synaptophysin within the
DHP of hBDNFVal/Val mice (Figure 5a), expression of the
postsynaptic marker PSD-95 within the mPFC also corresponded
with the FST performance of the hBDNFVal/Val group (Figure 5h).
However, these subtle genotype-mediated changes in synaptic
Figure 6. Chronic CORT alters the expression of the NMDA NR2A, NR2B and NR1 subunit composition independent of hBDNFVal66Met
genotype. Chronic CORT treatment was found to decrease (a) NR2A, (b) NR2B and (c) NR1 subunit expression in the DHP. In the VHP, chronic
CORT increased the expression of (d) NR2A and (e) NR2B but had no effect on the expression of (f) NR1. In the mPFC, the only group
difference to emerge was an effect of CORT on (h) NR2B, which also increased the expression of this subunit. No modulatory effect of
hBDNFVal66Met genotype emerged for the (g) NR2A or (i) NR1 subunits in this region. All data presented as mean± s.e.m.; *Po0.05, **Po0.01,
***Po0.001, and ****Po0.0001. Per group, n= 13–14.
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reorganization did not appear to influence NMDA receptor
subunits (Figure 6), despite PSD-95 anchoring this receptor and
previous studies finding that the Val66Met substitution alters
synaptic physiology that requires this receptor in the
hippocampus50 and infralimbic cortex.51 These experiments thus
yield evidence of subtle synaptic reorganization as would be
expected following a history of CORT or stress exposure, but
implicate that these changes are mostly independent of the
Val66Met variant.
Nonetheless, the current study has also yielded several
surprising observations worthy of discussion. The first of these
was a lack sex differences on the FST response, either as a product
of prior CORT treatment or hBDNFVal66Met genotype. This is
incongruent with data that chronic CORT exposure may elicit sex-
specific effects in rodents on the FST,65 although it is worth noting
that not all studies have observed such differences.66 Nonetheless,
the Val66Met polymorphism has been associated with sex-specific
risk of depression,67 albeit inconsistently too (for review, see ref.
15). While we have observed sex-specific effects in our
hBDNFVal66Met polymorphic mice (for example, startle reactivity,
see ref. 37, and other unpublished data not relevant to this
manuscript), we do not observe differences for many other
phenotypes (for example, hippocampus-dependent behavior, see
ref. 31). This may suggest that the interaction between the
BDNFVal66Met polymorphism, stress and sex may be paradigm/
phenotype specific, or gated by other factors. While we did not
observe a sex-specific phenotype on the FST here, both at baseline
and following CORT, this report is nonetheless a clue that the
BDNFVal66Met variant may influence risk of mood disorders via an
effect on endogenous HPA axis homeostasis. It would be
interesting for further investigations to examine whether
hBDNFVal66Met genotype alters endogenous HPA axis reactivity,
both before and following a history of stress in male and female
mice. Prior studies using this mouse line have reported no
differences in CORT levels following restraint stress among
females,68 however other reports have reported increases in
circulating CORT, ACTH and hypothalamic CRH mRNA expression
following restraint stress in BDNF+/Met mice relative to wildtype
controls.25 Data implicating genotype differences in response to
early life stress,69,70 as well as HPA axis reactivity have also been
reported in humans.69,71–73 While the aim of the current study was
to evaluate and describe the long-term effects of chronic CORT
exposure on the brain, it would be of interest to conduct an
environmentally salient stress challenge or dexamethasone
challenge following termination and wash-out of our CORT
treatment to examine if lasting change in HPA-axis reactivity
from prior stress are gated by hBDNFVal66Met genotype, as this may
provide additional insight into prior reports that hBDNFVal66Met
mice may be more vulnerable to stress in adulthood31,37 well after
the effects of CORT have washed-out.33
In summary, our data suggests that the BDNFVal66Met poly-
morphism gates stress-related learned helplessness and that this
is likely to occur via divergent pathways between the BDNFVal/Val
and BDNFMet/Met genotype groups. While there may be overlap in
these pathways, it appears there are separable effects of chronic
CORT treatment between the two genotype groups. Our results
implicate that TH expression within the mPFC and behavioral
despair on the FST is disrupted in hBDNFMet/Met mice at baseline,
and that chronic CORT recapitulates these phenotypes in
hBDNFVal/Val wildtype mice. Further, we also identify that long-
term and genotype-specific effects of chronic CORT treatment are
more pronounced in hBDNFVal/Val mice whereby, in addition to TH
and behavioral despair, TrkB isoforms and select synaptic markers
are impacted within the corticohippocampal axis. These data thus
have important implications for the clinical literature, where an
effect of the BDNFVal66Met variant may be obscured should a
history of stress not be stratified for and analyzed as a covariate.
Furthermore, the molecular data reported here suggest that TH
expression is perturbed in the mPFC of hBDNFMet/Met mice, who
have a robust despair phenotype irrespective of CORT treatment
on the FST, and that in hBDNFVal/Val mice chronic CORT is sufficient
to recapitulate this TH expression profile and phenotype on the
FST. This knowledge suggests that catecholamine innervation of
the mPFC, likely by noradrenaline, may be a therapeutic target
that can be exploited to treat depression-related symptoms in
human BDNFVal66Met carriers. In particular, these data suggest that
it may be of value to more extensively trial the effectiveness of
selective noradrenergic reuptake inhibitors on depression symp-
tomology among BDNFVal66Met carriers. As such, further research
which seeks to delineate the effects of stress in BDNFVal66Met
carriers may eventually lead to advances in our knowledge of how
common coding polymorphisms influence mood disorders, which
could be utilized to predict risk and tailor intervention strategies.
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